On August 21, 2020 Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of unique immunotherapies, reported that it has reached the enrolment target of 50 patients and that it has finalized recruitment of patients to all study arms of its ongoing VB N-01 phase I/IIa clinical trial of the personalized VB10.NEO neoantigen cancer vaccine (Press release, Vaccibody, AUG 21, 2020, View Source [SID1234563927]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Michael Engsig, CEO of Vaccibody, said: "VB10.NEO is a groundbreaking approach to personalized cancer treatments and has a large commercial potential. We are thus very excited to have reached this important milestone for the VB N-01 trial. The initial clinical results presented at SITC (Free SITC Whitepaper) in November 2019 were very encouraging and we will communicate the next steps in the development of VB10.NEO in Q4 2020."
VB N-01 is a basket trial for patients with locally advanced or metastatic melanoma, non-small cell lung carcinoma, clear renal cell carcinoma as well as urothelial cancer or squamous cell carcinoma of the head and neck. In the trial the safety, feasibility and efficacy of treatment with the personalized VB10.NEO vaccine is evaluated, including one study arm evaluating the combination of VB10.NEO and bempegaldesleukin (NKTR-214) in patients with head and neck cancer. The trial has been recruiting patients from seven clinical sites in Germany.
Siri Torhaug, Chief Medical Officer of Vaccibody adds, "We are truly grateful to the patients for participating in the trial, to our investigators at the clinical trial sites, our supply chain partners and the dedicated Vaccibody team who has done a great job by finalizing the enrolment and ensuring successful manufacture of the patient specific VB10.NEO products despite the challenging COVID-19 situation. Further, we are pleased that the recruitment of patients distributes well across all of the six treatment arms."